CP
APLS

CenterBook Partners’s Apellis Pharmaceuticals APLS Stock Holding History

CenterBook Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,687
Closed -$1.46M – 470
2024
Q3 		$1.46M Buy
+50,687
New +$1.88M 0.09% 244

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

CenterBook Partners's APLS Position: Q4 2024 in Review

CenterBook Partners sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 50,687 shares — an estimated $1.46M sold.

CenterBook Partners first reported a position in APLS in Q3 2024 and held it in 1 quarter. The position peaked at $1.46M in Q3 2024. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • CenterBook Partners reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • CenterBook Partners sold 50,687 Apellis Pharmaceuticals shares in Q4 2024, an estimated $1.46M.
  • CenterBook Partners first reported a position in Apellis Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • CenterBook Partners's Apellis Pharmaceuticals position peaked at $1.46M in Q3 2024.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on CenterBook Partners's 13F filing for Q4 2024, filed 13 Feb 2025.